TABLE 2.
Clinical characteristics of patients in the presence/absence of hemorrhagic transformation (HT) groups.
| Variables | No HT (n = 633) | HT (n = 117) | P |
| Age, years (IQR) | 61 (53–68) | 63 (55–70) | 0.248 |
| Male, n (%) | 453 (71.6) | 90 (76.9) | 0.234 |
| Cigarette smoking, n (%) | 334 (52.8) | 54 (46.2) | 0.189 |
| Alcohol consumption, n (%) | 261 (41.2) | 53 (45.3) | 0.413 |
| Hypertension, n (%) | 315 (49.8) | 69 (59.0) | 0.067 |
| Diabetes mellitus, n (%) | 113 (17.9) | 26 (22.2) | 0.264 |
| Coronary heart disease, n (%) | 124 (19.6) | 22 (18.8) | 0.844 |
| Atrial fibrillation, n (%) | 54 (8.5) | 20 (17.1) | 0.004 |
| Previous stroke, n (%) | 84 (13.3) | 19 (16.2) | 0.391 |
| Dyslipidemia, n (%) | 262 (41.4) | 51 (43.6) | 0.658 |
| Antihypertensive therapy, n (%) | 246 (38.9) | 54 (46.2) | 0.139 |
| Hypoglycemic therapy, n (%) | 99 (15.6) | 22 (18.8) | 0.393 |
| Antiplatelet therapy, n (%) | 76 (12.0) | 22 (18.8) | 0.045 |
| Baseline SBP, mmHg (IQR) | 153 (138–165) | 157 (145–169) | 0.048 |
| Baseline DBP, mmHg (IQR) | 90 (81–98) | 89 (81–97) | 0.683 |
| Baseline blood glucose, mmol/L (IQR) | 7.5 (6.5–9.0) | 8.3 (6.9–10.2) | 0.007 |
| Baseline NIHSS score (IQR) | 8 (5–12) | 10 (5–13) | 0.042 |
| ONT, min (IQR) | 184 (140–230) | 184 (150–225) | 0.454 |
| TOAST | 0.005 | ||
| Large-artery atherosclerosis, n (%) | 225 (35.5) | 49 (41.9) | |
| Small-vessel occlusion, n (%) | 254 (40.1) | 26 (22.2) | |
| Cardioembolism, n (%) | 66 (10.4) | 18 (15.4) | |
| Other determined etiology, n (%) | 10 (1.6) | 2 (1.7) | |
| Undetermined etiology, n (%) | 78 (12.3) | 22 (18.8) | |
| ALP, U/L (IQR) | 75.1 (62.2–91.3) | 76.3 (62.5–97.6) | 0.617 |
| Globulin, g/L (IQR) | 27.0 (24.2–29.7) | 27.7 (25.3–30.3) | 0.022 |
HT, hemorrhagic transformation; IQR, inter quartile range; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; ONT, onset to needle time; TOAST, Trial of Org 10172 in acute stroke treatment; ALP, alkaline phosphatase.